The Jewish General Hospital, a McGill Teaching Hospital seeks applicants for a full time Medical Oncology position with an appointment in the McGill University Department of Oncology. Candidates at the Assistant or Associate Professor level are acceptable and should preferably have experience in clinical or bench research. This research could be in the area of clinical trials (we have an active department of experimental therapeutics) or in basic laboratory research related to cancer. The hospital has excellent clinical and research facilities.

Please send curriculum vitae to

Dr. L. Panasci, M.D.
Associate Director
Jewish General Hospital
3755 Cote Ste. Catherine
Montreal, Quebec
H3T 1E2, Canada

---

CHAIR, PHARMACOLOGY DEPARTMENT

St. Jude Children's Research Hospital, a private research institute, is recruiting a new chairperson for its established Department of Pharmacology. The appointee will be expected to lead an internationally recognized program in his/her area of interest and to shape the future direction of research within the institution, through faculty recruitment and by contributions to the institution's overall scientific leadership, as a member of the Institution's Executive Committee. The institute is currently undergoing major expansion, and has recently occupied a new 240,000 sf research tower, where substantial laboratory and office space has been reserved for the pharmacology chair. The department currently has 9 faculty, all of whom are NIH funded investigators, and the new chair will be expected to recruit additional faculty. The current departmental budget is approximately $3 million. The department interfaces with established basic science programs in Virology and Molecular Biology, Biochemistry, Immunology, and Tumor Cell Biology, and established clinical research programs in Hematology/Oncology, Pharmaceutical Sciences and Infectious Diseases. Appointment to the University of Tennessee graduate faculty is also possible. The Chair's salary will be provided through committed endowment funds, together with additional resources commensurate with the needs of a dynamic and productive individual.

Applicants should submit a curriculum vitae and the names and addresses of four references to: Dr. William E. Evans, Chair, Pharmacology Search Committee, St. Jude Children's Research Hospital, 332 North Lauderdale, Memphis, Tennessee 38105

---

ANNOUNCEMENT

40TH ANNUAL MEETING

RADIATION RESEARCH SOCIETY

March 14-18, 1992

Salt Lake City, Utah

The 40th annual meeting of the Radiation Research Society will be held in Salt Lake City, Utah March 14-18, 1992. In addition to platform and poster sessions, plenary lecture topics will include women's issues in science (P. Gilmor), chaos (L. Liebovitch), signal transduction (H. Moses). The ethics of clinical trials (S. Hellman), and oxidative stress (J. McCord). Symposia and workshops will cover a wide variety of subjects of importance to radiation studies.

For further information, contact:

Laura Fleming-Jones
Reston, Virginia
Telephone: (703) 648-3780
Fax: (703) 648-9176

or

Dr. James A. Belli, M.D.
Galveston, Texas
Telephone: (409) 772-3960
Fax: (409) 772-3387

---

Penn State College of Medicine - University Hospital
The Milton S. Hershey Medical Center

Basic and Clinical Aspects of Aromatase

The Third International Conference on Aromatase

June 14–17, 1992 • Royal Carlton Hotel • Bologna, Italy

Co-sponsors:

Penn State's College of Medicine
University of Maryland at Baltimore, School of Medicine
University of Bologna, Italy

Co-chairs:

Richard J. Santen, M.D. • Angela Brodie, Ph.D.

Scientific Committee:

E. Simpson, H. Brodie, C. Coombes, P. Hall, J. Hammond, O.
Johnston, M. Motta, P. Naftolin, C. Robinson, J. Richrds, P. Sileri

Program:

Gene Structure/Function: Chair—Richards
Mechanisms and Inhibitors 1: Chair—H. Brodie
Catalysis and Inhibitors 2: Chair—Fishman
Ovarian Aromatase and Growth Factor Effects 1 & 2:
Chair—Hillier
Pregnancy, Uterus, and the Future: Chair—Naftolin
Brain Aromatase: Chair—Martini
Aromatase in Testis and Prostate: Chair—Puest
Peripheral Aromatase and Breast Cancer: Chair—Santen, Siiteri
Breast Cancer and Inhibitors—Preclinical Studies:
Chair—A. Brodie

Abstract Deadline for Poster Session: April 1, 1992
Registration and Abstract Forms:

Jane C. Mihelic, Continuing Medical Education
Penn State's Milton S. Hershey Medical Center
P.O. Box 851, Hershey, PA 17033-0851
Phone: (717) 531-7965
Fax: (717) 533-6618

---

St. Jude Children's Research Hospital is an Affirmative Action/Equal Opportunity Employer
An event of historic importance was the recent appointment of Bernadine P. Healy, M.D., as the first woman Director of the National Institutes of Health. She comes to this position with impressive credentials and a positive program which exhibits a degree of leadership long needed at the top level of NIH administration. Faced with uncertainty, dissatisfaction, a potential erosion of intramural programs, a pervasive pessimism among the extramural scientists dependent on NIH for the lifeblood of their research funding, as well as a host of political problems, she is bringing a sense of direction to the country’s biomedical research leadership.

As described in the May 31, 1991 issue of Science, pp. 1242–1244, she quickly installed a women’s health program, allocated $30 million for funding of grant applications just below the priority cutoff line, and has unveiled ambitious plans for restoring the luster of the intramural programs and improving research on minority health problems. Furthermore, she will be playing a leading role in the knotty politics of developing new rules for funding academia’s indirect costs of research support. These and other initiatives have earned Dr. Healy much praise and respect for insight and determination, and augur well for continuation of the world leadership of the United States in biomedical science.

Her determination to foster a two-gender policy, ending a sex bias toward human biomedical research, what she has termed an “androgenic” focus, is forecast in an editorial she wrote for the July 25, 1991 issue of the New England Journal of Medicine (p. 274). She titled this the “Yentl syndrome” based upon the 19th century heroine of a short story, later made into a play and movie, by Isaac Bashevis Singer. Yentl had to disguise herself as a man to go to school and study the Talmud in a highly male-oriented Jewish Community of Eastern Europe.

Dr. Healy brings a long history of involvement in government. She was born in New York City, was graduated from Vassar College summa cum laude, and received her M.D. cum laude from Harvard Medical School in 1970. After training in cardiology and internal medicine at The Johns Hopkins School of Medicine, she joined its faculty in 1976. She served as deputy director of the White House Office of Science and Technology Policy, 1984–1985, and on many executive and congressional commissions and was executive secretary of the White House Science Council’s Panel on the Health of Universities. She also chaired an advisory panel that contributed to a report by the Congressional Office of Technology Assessment, entitled “Federally Funded Research: Decisions for a Decade.” Until her appointment as NIH director, she was Vice Chairman of the President’s Council of Advisors on Science and Technology. She also served as president of both the American Federation of Clinical Research and the American Heart Association and prior to accepting her present position was chairman of the Research Institute of the Cleveland Clinic Foundation. In this capacity she headed an organization of over 400 employees, managed a budget of $37 million, and was responsible for nine research departments, including basic and clinical research in cardiovascular disease, neurobiology, immunology, cancer, artificial organs, atherosclerosis, musculoskeletal disorders, and molecular biology. Dr. Healy is the author or coauthor of over 200 publications, mostly in cardiovascular medicine, and has served on editorial boards of numerous journals.

Sidney Weinhouse